Law360 (July 24, 2020, 11:47 AM EDT) -- Indivior PLC said Friday it has agreed to pay $600 million to settle charges related to its opioid treatment Suboxone, ending litigation and investigations into claims about the safety of the drug's film form that enforcers say constituted fraud and unfair competition.
Indivior said Friday it will pay $600 million to settle charges related to its opioid treatment Suboxone. (George Frey/Bloomberg via Getty Images) Indivior said in a statement Friday that the agreement covers claims from an April 2019 grand jury indictment alleging it falsely marketed its under-the-tongue Suboxone Film as a more childproof and less addictive version of the drug's...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!